Biopharma | April 05, 2026
Innovent Biologics’ OLN324 shows breakthrough results in vision disease study
The JADE trial enrolled 164 U.S. patients who initially received three monthly doses of OLN324 or faricimab, followed by 12 weeks off treatment with retreatment allowed only if disease recurred
